Recent Updates
Recently added Catalysts

M118

Phase 2

Coronary Artery Disease (CAD) | Small molecule | Cardiovascular |Johnson & Johnson|Last Updated: Oct 14, 2019

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment503
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00543400Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE)PHASE2 COMPLETED 503 — — Sep 1, 2007May 1, 2009Oct 14, 2019 - —
Unlock Drug Trial Details
Study Design & Arms
Interventions
NameTypeDescription
M118DRUGintravenous (IV) infusion
Unfractionated HeparinDRUGIV infusion
Unlock Study Design Details
Competitive Landscape -Coronary Artery Disease 99 trials
CompanyTickerTrialsLead PhaseDrugs
Novo Nordisk A/S Sponsored ADR Class BNVO5PHASE3Ziltivekimab, Tocilizumab, Dobutamine, NaCl 0.9%
Boston Scientific CorporationBSX9PHASE3Undisclosed
Novartis AG Sponsored ADRNVS4PHASE3Inclisiran
Alnylam Pharmaceuticals, IncALNY1PHASE3Zilebesiran
Viatris, Inc.VTRS1PHASE3Selatogrel
NewAmsterdam Pharma Company N.V.NAMS1PHASE3obicetrapib + ezetimibe daily
GE Healthcare Technologies Inc.GEHC3PHASE1Regadenoson
Abbott LaboratoriesABT12 — Undisclosed
HeartFlow, Inc.HTFL5 — Rosuvastatin
Medtronic PlcMDT3NAUndisclosed
Teleflex IncorporatedTFX2NAUndisclosed
AstraZeneca PLCAZN1 — Tezepelumab
BioCardia, Inc.BCDA1NAUndisclosed
Sanofi SA Sponsored ADRSNY1 — alirocumab /2week, statin ± ezetimibe
Johnson & JohnsonJNJ1NAUndisclosed
Orchestra BioMed Holdings, Inc.OBIO1NAUndisclosed
Rhythm Pharmaceuticals, Inc.RYTM2NAUndisclosed
Azienda Ospedaliera Universitaria Integrata VeronaVRNA2 — Undisclosed
Healthcare Services Group, Inc.HCSG1 — Undisclosed
Collegium Pharmaceutical, Inc.COLL1 — Flozin
Unlock Competitive Intelligence